ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor

Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug resistance. In a previous study, we identified a gene signature, consisting mainly of Kruppel-associated box (KRAB) domain containing zinc finger (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rink, Lori, Ochs, Michael F., Zhou, Yan, von Mehren, Margaret, Godwin, Andrew K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556080/
https://www.ncbi.nlm.nih.gov/pubmed/23372733
http://dx.doi.org/10.1371/journal.pone.0054477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556080/
https://www.ncbi.nlm.nih.gov/pubmed/23372733
http://dx.doi.org/10.1371/journal.pone.0054477

Ejemplares similares